Follicular lymphoma · 7 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Obinutuzumab monotherapy Variant #03 | — | R 166 941 | 21d | — | — | — | — | — |
Lenalidomide and Rituximab (R2) Variant #10 | — | R 86 746 | 35d | ~26.7 mo | — | ~24 | ~R 2 081 899 PFS proxy · indirect | 4 |
Bortezomib and Rituximab (VR) Variant #06 | — | R 64 235 | 35d | ~12.8 mo | — | ~12 | ~R 770 814 PFS proxy · indirect | 1 |
Rituximab and hyaluronidase monotherapy Variant #01 Partial | — | R 11 796 | 28d | — | — | — | — | 1 |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | 126.0 mo | — | 22 | R 1 143 PFS proxy | 2 |
Interferon alfa-2a monotherapy Variant #01 Partial | — | — | 7d | ~5.4 mo | ~17.5 mo | ~24 | — | 10 |
Placebo Partial | — | — | — | — | — | — | — | 1 |
7 of 7 regimens shown